D.A. Davidson & CO. Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)

D.A. Davidson & CO. raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 13.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 26,565 shares of the company’s stock after buying an additional 3,129 shares during the period. D.A. Davidson & CO.’s holdings in Novo Nordisk A/S were worth $2,748,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in NVO. Westside Investment Management Inc. boosted its holdings in Novo Nordisk A/S by 83.3% during the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock worth $130,000 after buying an additional 649 shares in the last quarter. Lazard Asset Management LLC raised its position in shares of Novo Nordisk A/S by 182.2% during the 3rd quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock valued at $135,883,000 after buying an additional 964,640 shares during the period. Ieq Capital LLC increased its position in shares of Novo Nordisk A/S by 136.6% during the third quarter. Ieq Capital LLC now owns 27,474 shares of the company’s stock valued at $2,498,000 after acquiring an additional 15,860 shares during the last quarter. One Capital Management LLC purchased a new stake in Novo Nordisk A/S during the third quarter worth about $203,000. Finally, Advisor Resource Council acquired a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $997,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target on the stock. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Trading Up 0.3 %

Shares of NVO traded up $0.47 on Friday, hitting $136.04. 2,845,222 shares of the stock traded hands, compared to its average volume of 4,075,833. The firm has a market capitalization of $610.48 billion, a P/E ratio of 46.90, a P/E/G ratio of 1.40 and a beta of 0.43. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The stock’s 50 day moving average is $128.21 and its two-hundred day moving average is $116.45.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.77 by $0.06. The business had revenue of $9.52 billion for the quarter, compared to the consensus estimate of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.43 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.